This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. Love it or hate it, no one can deny that Über has revolutionized the fundamental nature of the taxi

For startup and emerging biotech companies, corporate venture capital and direct corporate equity investing are critically important contributors on the spectrum of funding sources – and over the past fifteen years, their involvement as investors in young biotech companies appears

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Infectious disease has had an ebb and flow relationship with our general awareness; epidemics such as Zika, Ebola, and

It’s hard to believe how time flies, but I started this LifeSciVC biotech-blogging experiment five years ago today. Since that initial post in March 2011, exactly 250 blogs have gone live, making it an opportune time to step back and

This blog was written by Jason Gardner, Atlas EIR and founding CEO of a new stealth-stage startup, as part of the From The Trenches feature of LifeSciVC. What are you doing? This is the most frequent yet simple question that

This blog was written by Jose-Carlos Gutiérrez-Ramos, CEO of Synlogic, as part of the “From The Trenches” feature of LifeSciVC. When I was invited to contribute to this blog, I was determined to write first about patients with Rare Diseases and

Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing. After watching the carnage in 2016 wreck havoc with small

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After a long, challenging period for CNS R&D – marked by late-stage clinical failures, mass layoffs, and limited early-stage

The equity markets have softened tremendously in recent weeks and the NASDAQ Biotech Index has swooned to levels last held in late 2014, in line with other equity indices like the S&P500.  Triggered by significant and negative macro forces, this

This blog was written by Bill Marshall, CEO of MiRagen Therapeutics in Boulder, CO, as part of the “From The Trenches” feature of LifeSciVC. Dictionary.com defines “outlier” as: (1) something that lies outside the main body or group that it

2015 was the biggest year ever for venture capital funding into the biotech sector. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $7.4B was invested during the year.  Lots

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. The wifi is predictably not working on my flight back from the JP Morgan Healthcare Conference (#JPM16), allowing me the